Ciclosporin intravenous - Maas Biolab/NeuroVive

Drug Profile

Ciclosporin intravenous - Maas Biolab/NeuroVive

Alternative Names: CicloMulsion; Ciclosporin-A; Cyclosporin - Maas Biolab; Cyclosporin-A; Mitogard; Neuro-STAT®; NeuroSTAT

Latest Information Update: 09 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Maas Biolab; NeuroVive Pharmaceutical
  • Developer Defense Threat Reduction Agency; Maas Biolab; NeuroVive Pharmaceutical; Skane University Hospital; Walter Reed Army Institute of Research
  • Class Anti-inflammatories; Antineoplastics; Antipsoriatics; Antirheumatics; Ciclosporins; Eye disorder therapies; Heart failure therapies; Neuroprotectants
  • Mechanism of Action Calcineurin inhibitors; Cyclophilin inhibitors; Free radical inhibitors; Immunosuppressants; Mitochondrial permeability transition pore inhibitors; P-glycoprotein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis; Brain injuries
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Brain injuries
  • Discontinued Acute kidney injury; Amyotrophic lateral sclerosis; Poisoning; Reperfusion injury

Most Recent Events

  • 04 Oct 2018 NeuroVive in collaboration with the University of Florida completes the biomarker research to support development of ciclosporin intravenous for Brain injuries
  • 04 Oct 2018 NeuroVive plans a phase II clinical efficacy trial for Traumatic brain injury in 2019
  • 06 Sep 2018 NeuroVive announces intention to submit IND to the US FDA for Traumatic brain injury
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top